WO2010097643A1 - Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite - Google Patents

Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite Download PDF

Info

Publication number
WO2010097643A1
WO2010097643A1 PCT/HR2009/000005 HR2009000005W WO2010097643A1 WO 2010097643 A1 WO2010097643 A1 WO 2010097643A1 HR 2009000005 W HR2009000005 W HR 2009000005W WO 2010097643 A1 WO2010097643 A1 WO 2010097643A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
polyoxyethylene
acid
substances
sodium
Prior art date
Application number
PCT/HR2009/000005
Other languages
French (fr)
Inventor
Antonio Lelas
Ivica Cepanec
Original Assignee
Novatech Istrazivanje D.O.O.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novatech Istrazivanje D.O.O. filed Critical Novatech Istrazivanje D.O.O.
Priority to PCT/HR2009/000005 priority Critical patent/WO2010097643A1/en
Publication of WO2010097643A1 publication Critical patent/WO2010097643A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds

Definitions

  • the present invention relates to a formulation comprising micronized zeolite, green tea extract, genistein, and one or more optional ingredients which is used as an effective therapeutic agent for reduction of body weight and cellulite.
  • the present invention solves technical problem of efficient reduction of body weight and cellulite, based on formulation consisting of variable portions of:
  • micronized zeolite (MZ) of general formula:
  • Me Na, K, Mg, Ca, Fe, Zn, Mn, Cr; whereas ratio of silicon to aluminium, y:x is between 6:1 to 1 :1 ; number of crystalline water m is from 0 to 20, which is characterized by particles size ⁇ 5 ⁇ m; in concentrations from 1-50%, most preferably from 3-30%;
  • Green tea extract containing at least 30% of epigallocatechin gallate (EGCG; 1), and 5% of caffeine (2); in concentrations from 0.1-90%, most preferably from 20-90%; 1
  • EGCG epigallocatechin gallate
  • excipients which yield in desired pharmaceutical or cosmetic form: tablets, capsules, ointments, creams, gels, lotions, shampoos, powders, liquid powders, syrups, suspensions, and therapeutic patches; in concentrations from 1-98.85%, most preferably from 10-75%.
  • Obesity condition is one of the major risk factors for a numerous diseases of modern people such as hypertension, increased blood triglycerides and cholesterol, atherosclerosis, diabetes, etc. Increased body weight also causes several cosmetic disadvantages in both female and male subjects.
  • One of the most known conditions within female population is enhanced occurrence of cellulite.
  • the obesity and accompanied condition of cellulite in female subjects can be treated with numerous commercial herbal and over-the-counter preparations. Some of them are based on natural substances which physically adsorbs fatty substances in the gastrointestinal (GI) tract. In this manner they impair absorption of fats in GI tract, and help to eliminate them by feces. Other active substances act at some levels of metabolism by speeding-up the catabolism of triglycerides.
  • GI gastrointestinal
  • Green tea extract due to its content of epigallocatechin gallate (1), and caffeine (2) has been used for treatment of obesity, cellulite, and associated metabolic syndrome both as single ingredient or in combinations with kidney bean extracts [G. S. Birketvedt, CA2627314 (2007)], pregnane glycosides [R. Kamala, R. Ramaswamy, CA2563952 (2005)], pine needle extract [J. Y. Kim, KR20040089258 (2004)], etc.
  • EGCG (1) is effective in treatment of obesity due to its strong lipolytic and antioxidative effects:
  • (iii) inhibits the lipid accumulation in 3T3-L1 cells, generally reduces adipose tissue mass, and promote thermogenesis and fat oxidation at obesity condition
  • Caffeine (2) promotes lipolysis upon metabolic conversion to paraxanthine (under the action of cytochrome P450 oxidase). In this manner it can raise concentration of triglycerides lipolytic products: glycerol and higher fatty acids.
  • Green tea extract helps reduction of body weight and cellulite by combination of the following pathways:
  • Genistein (3) has been described as an effective agent for treatment of obesity [I. Schoenmakers, C. Z. Dang, M. G. W. C. L ⁇ wik, B. L. A. Van Helvoort, R. Hageman, WO 03/068218 Al (2003); C. Prasad, E. J. Figueroa, P. Vijayagopal, US2006182825 Al (2006)].
  • genistein Due to the fact that cellulite formation is basically inflammatory process, observed effects of genistein are responsible for its anti-cellulite action. Moreover, by inhibiting blood glucose concentration (hypoglycemic effect), genistein also contributes to lowering of fatty acids level and thus subsequently triglycerides biosynthesis [S. Y. Cheng, N. S. Shaw, K. S. Tsai, C. Y. Chen: The hypoglycemic effects of soy isoflavones on postmenopausal women, J. Womens Health (Larchmt) 13 (2004) 1080-1086; E. A. Pop, L. M. Fischer, A. D. Coan, M. Gitzinger, J. Nakamura, S. H.
  • the present invention relates to the formulation consisting of variable amounts of:
  • micronized zeolite (MZ) of general formula:
  • Me Na, K, Mg, Ca, Fe, Zn, Mn, Cr; whereas ratio of silicon to aluminum, y:x is between 6:1 to 1 :1; number of crystalline water m is from 0 to 20, which is characterized by particles size ⁇ 5 ⁇ m; in concentrations from 1-50%, most preferably from 3-30%;
  • Green tea extract containing at least 30% of epigallocatechin gallate (EGCG; 1), and 5% of caffeine (2); in concentrations from 0.1-90%, most preferably from 20-90%;
  • EGCG epigallocatechin gallate
  • excipients which yield in desired pharmaceutical or cosmetic form: tablets, capsules, ointments, creams, gels, lotions, shampoos, powders, liquid powders, syrups, suspensions, and therapeutic patches; in concentrations from 1-98.85%, most preferably from 10-75%.
  • the formulation from the present invention provides highly effective reduction of body weight and cellulite.
  • micronized zeolite clinoptilolite, or similar zeolites like zeolite A when administered orally with Green tea extract and genistein surprisingly does act as very effective composition for treatment of obesity and cellulite.
  • Silicon as essential microelement with a number of roles in human organism is biologically available in the form of ortho-silicic acid (H 4 SiO 4 ).
  • silicon acts as anti- inflammatoric in various conditions and diseases such as seborrheic dermatitis, neurodermitis, atopic dermatitis, skin irritations, disorders connected with decubitus, accelerates wound healing, and stimulates biosynthesis of skin building proteins collagen and elastin [C. D. Seaborn, F. H. Nielsen: Silicon deprivation decreases collagen formation in wounds and bone, and ornithine transaminase enzyme activity in liver, Biol. Trace Element Res. 89 (2002) 251; M. R. Calomme, D. A. V. Berghe: Supplementation of calves with stabilised orthosilicic acid effect on the Si, Ca, Mg and P concentration in serum and the collagen concentration in skin and cartilage, Biol. Trace Element Res. 56 (1997) 153].
  • silicon takes a part in the structure of arterial, veins, and capillary walls; increases elasticity and hardness of blood vessels, and decreased their permeability [K. Schwartz: A bound form of silicon in glycosaminoglycans and polyuronides, Proc. Nat. Acad. Set USA 70 (1973) 1608; E. M. Carlisle, D. L. Garvey: The effect of silicon on formation of extra-cellular matrix components by chondrocytes in culture, Fed. Proc. 41 (1982) 461; E. M. Carlisle, C. Suchil: Silicon and ascorbate interaction in cartilage formation in culture, Fed. Proc. 42 (1983) 398].
  • micronized zeolite clinoptilolite acts as effective pharmaceutically-acceptable source of highly bioavailable silicon.
  • MZ is capable of releasing soluble silicon even in neutral water, presumably in the form of ortho-silicic acid, as demonstrated by quantitative analyses of aqueous supernatants obtained after trituration of MZ in pure redistilled water [Novatech, PCT7HR2008/000030].
  • micronized zeolit clinoptilolite in all suitable pharmaceutical forms Na + , K + , Mg 2+ , Ca 2+ , Fe 2+ /Fe 3+ , Zn 2+ , Mn 2+ , Cr 3+ .
  • suitable pharmaceutical forms Na + , K + , Mg 2+ , Ca 2+ , Fe 2+ /Fe 3+ , Zn 2+ , Mn 2+ , Cr 3+
  • zeolite A can be used after micronization.
  • ortho-Silicic acid forms relatively stable complexes with ortho-diphenols like EGCG, and ⁇ -diketons or ⁇ -keto-enols (or analogous ⁇ -keto-phenols) such as genistein. In this manner it might enhance biological activity of these polyphenols by keeping their at sufficient concentrations in body fluids. This might occur due to decreased rate of their metabolism in liver through known polyphenols-elimination pathway by glucuronidation or sulfate-conjugation.
  • the formulation of the present invention is consisting of the mentioned components in the following concentrations:
  • micronized zeolite (MZ) of general formula:
  • Me Na, K, Mg, Ca, Fe, Zn, Mn, Cr; whereas ratio of silicon to aluminum, y:x is between 6:1 to 1 :1 ; number of crystalline water m is from 0 to 20, which is characterized by particles size ⁇ 5 ⁇ m; in concentrations from 1-50%, most preferably from 3-30%; (ii) Green tea extract containing at least 30% of epigallocatechin gallate (EGCG; 1), and 5% of caffeine (2); in concentrations from 0.1-90%, most preferably from 20-90%;
  • EGCG epigallocatechin gallate
  • excipients which yield in desired pharmaceutical or cosmetic form: tablets, capsules, ointments, creams, gels, lotions, shampoos, powders, liquid powders, syrups, suspensions, and therapeutic patches; in concentrations from 1-98.85%, most preferably from 10-75%.
  • Tablets, capsules, syrups, suspensions and therapeutic patches are preferred pharmaceutical forms for oral administration in treatment of obesity conditions, whereas forms such as ointments, creams, gels, lotions, shampoos, powders, liquid powders, and therapeutic patches are more suitable for topical treatment of cellulite.
  • Excipients are selected from the groups consisting of fillers, binders, disintegrants, lubricants, emollients, emulsifiers, tensides, humectants, solvents, thickeners, preservatives, antioxidants, stabilizers, and other functional additives which may help basic therapeutic action of above- defined main active substances.
  • fillers are selected from the group consisting of microcrystalline cellulose, lactose monohydrate, calcium hydrogenphosphate, sorbitol, starch, modified starches, etc.
  • the following substances can be used: talc, kaolin, bentonite, montmorillonite, precipitated calcium carbonate, basic magnesium carbonate, calcium silicate, aluminum hydroxide, silicon dioxide, or mixtures of these substances.
  • binders are selected from the group consisting of gelatin, lactose monohydrate, sorbitol, saccharose, xylitol, maltitol, mannitol, starch, modified starches, methylcellulose, 2-hydroxyethylcellulose, 2-hydroxypropylcellulose, sodium carboxymethylcellulose, polyethyleneglycols, polyglycerols, polyvinylpyrrolidone, polyvinylpyrrolidone co-polymers, carrageenans, or mixtures of these substances.
  • Disintegrants in solid dosage forms are selected from the group consisting of starch, modified starches, sodium starch glycolate, methylcellulose, sodium carboxymethylcellulose, 2- hydroxyethylcellulose, 2-hydroxypropylcellulose, polyvinylpyrrolidone, polyvinylpyrrolidone co-polymers, or mixtures of these substances.
  • Lubricants in solid dosage forms and powders are selected from the group consisting of: metal soaps such as magnesium stearate, calcium stearate, and zinc stearate; higher fatty acids like stearic acid; talc; silicon dioxide; or mixtures of these substances.
  • Emollients in semi-solid and liquid forms of the formulation for topical treatment of cellulite are selected from the group consisting of: paraffin wax; mineral oil; petroleum jelly; ozokerite; synthetic esters of higher fatty acids like isopropyl myristate, isopropyl palmitate, trimethylolpropane tristearate, glyceryl tricaprylate; natural waxes such as beeswax or spermaceti; liquid natural waxes such as jojoba oil; synthetic waxes such as lauryl laurate; plant oils such as soybean oil, sweet almond oil, sunflower seed oil, fish oil, olive oil, wheat germ oil, corn germ oil, avocado oil, palm oil, coconut oil; semi-solid or liquid silicones; higher fatty alcohols such as cetyl alcohol, stearyl alcohol, oleyl alcohol; or mixtures of these substances.
  • Emulsifiers in creams, ointments, and other forms of the formulation are selected from the group consisting of: metal salts of sulphates of higher fatty alcohols like sodium laurylsulphate, sodium lauryl ethyleneglycolsulphate, sodium lauryl diethyleneglycolsulphate; ethoxylates of higher fatty alcohols such as polyoxyethylene(2) laurylether, polyoxyethylene(l ⁇ ) laurylether, polyoxyethylene(23) laurylether, and others, where 2, 10 and 23 represent average number of ethyleneglycol units bounded on higher fatty alcohol; ethoxylates of higher fatty acids such as polyoxyethylene(2) laurate, polyoxyethylene(l ⁇ ) laurate, polyoxyethylene(23) laurate, and others, wherein 2, 10 and 23 represent average number of ethyleneglycol units bounded on higher fatty acid; esters of sorbitan such as polyoxyethylene sorbitan monolaurate; lanolin;
  • Tensides in liquid forms of the formulation like shampoos are selected from the group consisting of: metal salts of sulphates of higher fatty alcohols such as sodium laurylsulphate, sodium lauryl ethyleneglycolsulphate, sodium lauryl diethyleneglycolsulphate, potassium laurylsulphate, potassium lauryl ethyleneglycolsulphate, potassium lauryl diethyleneglycolsulphate, ammonium laurylsulphate, ammonium lauryl ethyleneglycolsulphate, ammonium lauryl diethyleneglycolsulphate, sodium or potassium cocoamphodipropionate; disodium or dipotassium cocoamphodiacetate; polyoxyethylene(l ⁇ ) laurylether, polyoxyethylene(23) laurylether, polyoxyethylene(l ⁇ ) stearylether, polyoxyethylene(23) stearylether, polyoxyethylene(l ⁇ ) oleylether, polyoxyethylene(23) oleylether, and other ethoxylates of higher
  • mono- or diethanolamides of higher fatty acids cocoamidopropyl betaine; glycosides of higher fatty alcohols like cocoglucoside; sodium or potassium di(2-ethylhexyl)sulfosuccinate; disodium or dipotassium 2-ethylhexylsulfosuccinate; cationic tensides such as cetyltrimethylammonium bromide, didecyldimethylammonium chloride, benzalkonium chloride, cetylbenzyldimethylammonium bromide, cetylpyridinium chloride; metal salts of higher fatty acids such as sodium or potassium salts of lauric, myristic, palmitic, stearic, oleic, or ricinoleic acid; or mixtures of these substances.
  • Humectants are selected from the group consisting of glycerol, 1 ,2-propyleneglycol, 1,3- propyleneglycol, hexyleneglycol, 1,3-butanediol, polyethyleneglycols, polyglycerols, sorbitol, xylitol, saccharose, urea, sodium hyaluronate, or mixtures of these substances.
  • Solvents in liquid forms of the formulation like lotions are selected from the group consisting of purified water, ethanol, 1-propanol, isopropanol, isosorbide dimethylether, diethyleneglycol monomethylether, diethyleneglycol dimethylether, diethyleneglycol monoethylether, diethyleneglycol diethylether, triethyleneglycol monomethylether, triethyleneglycol dimethylether, triethyleneglycol monoethylether, triethyleneglycol diethylether, ethyl lactate or other lactate esters with lower aliphatic alcohols, triethylhexanoin, or mixtures of these substances.
  • Thickeners in the formulation are selected from the group consisting of: polyacrylic acid, its co-polymers, or their sodium, potassium, or triethanolamine salts; methylcellulose; sodium carboxymethylcellulose; 2-hydroxyethylcellulose; 2-hydroxypropylcellulose; starch; modified starches; polyglycerols; polyethyleneglycols; gelatin; pectin; agar agar; carrageenans; gum arabic; alginic acid; sodium alginate; montmorillonite; bentonite; or mixtures of these substances.
  • Preservatives are selected from the group consisting of: methyl 4-hydroxybenzoate; ethyl 4- hydroxybenzoate; propyl 4-hydroxybenzoate; butyl 4-hydroxybenzoate; triclosan; chlorhexidine or its dihydrochloride, diacetate, or digluconate salts; sorbic acid; potassium sorbate; benzoic acid; sodium benzoate; 2-bromo-2-nitropropane-l,3-diol; 2- hydroxybiphenyl; 2-phenoxyethanol; 4-chloro-m-cresol; thymol; eugenol; methyl salicylate; or mixtures of these substances.
  • Antioxidants are selected from the group consisting of 2,6-di-terc-butyl-4-hydroxytoluene (BHT), terc-butylhydroxyanisole (BHA), tocopherol, tocopherol acetate, ascorbic acid, ascorbyl palmitate, or mixtures of these substances.
  • Stabilizers are selected from the group consisting of disodium ethylenediamine tetraacetate (Na 2 EDTAx2H 2 O), disodium N-(2-hydroxyethyl)ethylenediamine triacetate
  • Anti-inflammatory and/or antiphlogistic agent is selected from the group consisting of: paracetamol; metamizol sodium; acetylsalicylic acid and its salts with pharmaceutically acceptable bases; salicylic acid and its salts with pharmaceutically acceptable bases; salsalate; methyl salicylate; ethyl salicylate; benzyl salicylate; 2-hydroxyethyl salicylate; salicylamide; phenylbutazone sodium; propyphenazone; oxyphenbutazone; mofebutazone; bumadizon calcium; phenazone; ethenzamide; ketoprofen, ibuprofen, naproxen, flurbiprofen, pirprofen, mefenamic acid, fluphenamic acid, thiaprofenic acid or their salts with pharmaceutically acceptable bases; diclofenac sodium; indomethacin; piroxicam; meloxicam; codeine; caffeine; extract of St John's wort (Hy
  • Antioxidant is selected from the group consisting of: extract of Rooibos (Aspalathus linearis); extract of Nettle (Urtica dioica); extract of Bilberry (Vaccinium myrtillus); extract of Orange (Citrus aurantium); silymarin; extract of Milk Thistle (Silybum marianum); ascorbic acid, its salts, and esters such as ascorbyl palmitate; tocoferol; tocoferol acetate; niacinamide; rutin; quercetin; extracts of plants with significant content of rutin and/or quercetin; cyanidin; hesperidin; diosmin; lycopene; extracts of plants with significant contents of lycopene; resveratrol; tetrahydrocurcumin; rosmarinic acid; extract of Rosemary (Rosmarinus officinalis); hypericin; extract of St John's wort (Hypericum perforatum); ella
  • Astringent is selected from the group consisting of: zinc oxide; zinc stearate; zinc tannate; zinc acetate; zinc sulphate; zinc chloride; iron(III) chloride; aluminum sulphate; potassium aluminum sulphate; aqueous basic aluminum acetate; aluminum acetotartarate; bismuth subnitrate; bismuth subcarbonate; bismuth phosphate; bismuth tannate; calamine; copper(II) sulphate; silver nitrate; silver-proteine; aescin; extract of Horse-Chestnut (Aesculus hippocastanum); Balsam of Peru; silica gel; kaolin; talc; titanium dioxide; tannic acid; albumin tannate; methylene ditannate; extracts with significant content of tannins such as extracts of Oak bark (Cortex Quercus ruber, Quercus sessiliflora), Bearberry leaves (Arctostaphylos uvae
  • Skin tonifying agents are selected from the group consisting of: vitamins and pro-vitamins like retinol palmitate, ⁇ -carotene, niacinamide, d-panthenol, calcium pantothenate, folic acid, riboflavin, pyridoxine, thiamine, biotin, cyanocobalamin, ascorbic acid its salts and esters such as ascorbyl palmitate, cholecalciferol, tocopherol, tocopherol acetate, phylloquinone, menaquinone, menadione; animal and plant oils with high contents of omega-3 higher fatty acids such as fish or linseed oil; choline chloride; protein hydrolysates; algae extracts; extract of Witch-hazel (Hamamelis virginiana); extract of Centaurium (Erythraea centaurum); extract of Mullein (Verbascum phlomoides); extract of European Holly (Ilex aquifoli
  • the formulation of the present invention can be in the form of tablets, capsules, ointments, creams, gels, lotions, shampoos, powders, liquid powders, syrups, suspensions, and therapeutic patches.
  • the formulations are produced by common procedures known to those skilled in the art of cosmetic and/or pharmaceutical technology [S. C. Gad (Ed.): Pharmaceutical Manufacturing Handbook: Production and Processes, Wiley (2008)]. Several possible variations are possible but which essentially remain under the scope of this invention. EXAMPLES
  • micronized zeolite (MZ) in all possible forms Na, K, Mg, Ca, Fe, Zn, Mn, Cr
  • Zeolite A and natural clinoptilolite were purchased and micronized in our laboratory.
  • room temperature means: 20-25 0 C.
  • Composition per cps 50 mgs of genistein; 390 mgs of Green tea extract (corresponds to 175 mgs of EGCG and 40 mgs of caffeine); and 50 mgs of micronized clinoptilolite.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to a pharmaceutical formulation based on variable portions of: (i) micronized zeolite (MZ) of general formula: (Men+) x/n[(AI02)x(Si02)y].mH20 (MZ) wherein Me= Na, K, Mg, Ca; whereas ratio of silicon to aluminum, y:x is between 6:1 to 1:1; number of crystalline water m is from 0 to 20, which is characterized by particles size < 5 μm; in concentrations from 1-50%, most preferably from 3-30%; (ii) Green tea extract containing at least 30% of epigallocatechin gallate (EGCG), and 5% of caffeine; in concentrations from 0.1-90%, most preferably from 20-90%; (iii) genistein; in concentrations from 0.05-20%, most preferably from 1-10%; and (iv) one or more excipients which yield in desired pharmaceutical or cosmetic form: tablets, capsules, ointments, creams, gels, lotions, shampoos, powders, liquid powders, syrups, suspensions, and therapeutic patches; in concentrations from 1-98.85%, most preferably from 10-75%; which is useful for highly effective reduction of body weight and cellulite.

Description

FORMULATION BASED ON MICRONIZED ZEOLITE, GREEN TEA EXTRACT, AND GENISTEIN AS A THERAPEUTIC AGENT FOR REDUCTION OF BODY
WEIGHT AND CELLULITE
DESCRIPTION
THE FIELD OF THE INVENTION
The present invention relates to a formulation comprising micronized zeolite, green tea extract, genistein, and one or more optional ingredients which is used as an effective therapeutic agent for reduction of body weight and cellulite.
THE SUMMARY OF THE INVENTION
The present invention solves technical problem of efficient reduction of body weight and cellulite, based on formulation consisting of variable portions of:
(i) micronized zeolite (MZ) of general formula:
Figure imgf000002_0001
wherein Me= Na, K, Mg, Ca, Fe, Zn, Mn, Cr; whereas ratio of silicon to aluminium, y:x is between 6:1 to 1 :1 ; number of crystalline water m is from 0 to 20, which is characterized by particles size < 5 μm; in concentrations from 1-50%, most preferably from 3-30%;
(ii) Green tea extract containing at least 30% of epigallocatechin gallate (EGCG; 1), and 5% of caffeine (2); in concentrations from 0.1-90%, most preferably from 20-90%;
Figure imgf000003_0001
1
(iii) genistein (3); in concentrations from 0.05-20%, most preferably from 1-10%;
Figure imgf000003_0002
3 and
(iv) one or more excipients which yield in desired pharmaceutical or cosmetic form: tablets, capsules, ointments, creams, gels, lotions, shampoos, powders, liquid powders, syrups, suspensions, and therapeutic patches; in concentrations from 1-98.85%, most preferably from 10-75%.
PRIOR ART
Obesity condition is one of the major risk factors for a numerous diseases of modern people such as hypertension, increased blood triglycerides and cholesterol, atherosclerosis, diabetes, etc. Increased body weight also causes several cosmetic disadvantages in both female and male subjects. One of the most known conditions within female population is enhanced occurrence of cellulite.
The obesity and accompanied condition of cellulite (in female subjects) can be treated with numerous commercial herbal and over-the-counter preparations. Some of them are based on natural substances which physically adsorbs fatty substances in the gastrointestinal (GI) tract. In this manner they impair absorption of fats in GI tract, and help to eliminate them by feces. Other active substances act at some levels of metabolism by speeding-up the catabolism of triglycerides.
Among them, Green tea extract [S. Sang, J. D. Lambert, C-T. Ho, C. S. Yang: Green Tea Polyphenols, Encyclopedia of Dietary Supplements, Marcel&Dekker (2005) 327-336] due to its content of epigallocatechin gallate (1), and caffeine (2) has been used for treatment of obesity, cellulite, and associated metabolic syndrome both as single ingredient or in combinations with kidney bean extracts [G. S. Birketvedt, CA2627314 (2007)], pregnane glycosides [R. Kamala, R. Ramaswamy, CA2563952 (2005)], pine needle extract [J. Y. Kim, KR20040089258 (2004)], etc.
EGCG (1) is effective in treatment of obesity due to its strong lipolytic and antioxidative effects:
(i) antioxidative effect; In isolated myocytes it inhibited ouabain-induced reactive oxygen species (ROS) production and cell proliferation;
(ii) it reduces the levels of cholesterol, triglycerides, and lipid peroxides in serum; and
(iii) inhibits the lipid accumulation in 3T3-L1 cells, generally reduces adipose tissue mass, and promote thermogenesis and fat oxidation at obesity condition [H.-S. Moon, C-S. Chung, H.-G. Lee, T.-G. Kim, Y.-J. Choi, C-S. Cho: Inhibitory Effect of (-)- Epigallocatechin-3 -Gallate on Lipid Accumulation of 3T3-L1 Cells, Obesity 15 (2007) 2571-2582; M. Boschmann, F. Thielecke: The Effects of Epigallocatechin-3-Gallate on Thermogenesis and Fat Oxidation in Obese Men: A Pilot Study, J. Am. Coll. Nutr. 26 (2007) 389S-395S; S. Wolfram, D. Raederstorff, Y. Wang, S. R. Teixeira, V. Elste, P. Weber: TEAVIGO™ (Epigallocatechin Gallate) Supplementation Prevents Obesity in Rodents by Reducing Adipose Tissue Mass, Ann. Nutr. Metab. 49 (2005) 54-63].
Caffeine (2) promotes lipolysis upon metabolic conversion to paraxanthine (under the action of cytochrome P450 oxidase). In this manner it can raise concentration of triglycerides lipolytic products: glycerol and higher fatty acids.
In conclusion, Green tea extract helps reduction of body weight and cellulite by combination of the following pathways:
(i) preventively, by strong antioxidative action of EGCG and related polyphenols; and (ii) curatively, by lipolytic action of both EGCG (1) and caffeine (2) or its main metabolite paraxanthine.
Genistein (3) has been described as an effective agent for treatment of obesity [I. Schoenmakers, C. Z. Dang, M. G. W. C. Lόwik, B. L. A. Van Helvoort, R. Hageman, WO 03/068218 Al (2003); C. Prasad, E. J. Figueroa, P. Vijayagopal, US2006182825 Al (2006)].
Studies conducted on ovariectomized female mices showed that genistein leads to the following biological effects [H.-K. Kim, C. Nelson-Dooley, M. A. Della-Fera, J.-Y. Yang, W.
Zhang, J. Duan, D. L. Hartzell, M. W. Hamrick, C. A. Baile: Genistein Decreases Food
Intake, Body Weight, and Fat Pad Weight and Causes Adipose Tissue Apoptosis in
Ovariectomized Female Mice, J. Nutr. 136 (2006) 409-414]:
(i) decreased food intake;
(ii) reduced body weight;
(iii) decreased fat pad weight; and
(iv) causes adipose tissue apoptosis.
Studies in isolated rat adipocytes showed that genistein possesses anti-obesity and anti- cellulite action through at least three different pathways [K. Szkudelska, L. Nogowski, T. Szkudelski: Genistein affects lipogenesis and lipolysis in isolated rat adipocytes, J. Steroid Biochem. MoI. Biol. 75 (2000) 265-271]: (i) by significant reduction of glucose conversion to total lipids (confirmed in experiments with both in presence and absence of insulin); (ii) by reduction of fatty acids synthesis; and (iii) by their esterification to lipids.
Due to the fact that cellulite formation is basically inflammatory process, observed effects of genistein are responsible for its anti-cellulite action. Moreover, by inhibiting blood glucose concentration (hypoglycemic effect), genistein also contributes to lowering of fatty acids level and thus subsequently triglycerides biosynthesis [S. Y. Cheng, N. S. Shaw, K. S. Tsai, C. Y. Chen: The hypoglycemic effects of soy isoflavones on postmenopausal women, J. Womens Health (Larchmt) 13 (2004) 1080-1086; E. A. Pop, L. M. Fischer, A. D. Coan, M. Gitzinger, J. Nakamura, S. H. Zeisel: Effects of a high daily dose of soy isoflavones on DNA damage, apoptosis, and estrogenic outcomes in healthy postmenopausal women: a phase I clinical trial, Menopause 15 (2008) 684-692; G. Rimbach, C. Boesch-Saadatmandi, J. Frank, D. Fuchs, U. Wenzel, H. Daniel, W. L. Hall, P. D. Weinberg: Dietary isoflavones in the prevention of cardiovascular disease-a molecular perspective, Foo d. Chem. Toxicol. 46 (2008) 1308-1319]. In this manner, genistein acts not only on reduction of biosynthesis of lipids, but also on elimination (adipocite apoptosis) of already present fat deposites.
Technical problem of effective reduction of body weight and treatment of cellulite is solved on a new and more efficient manner as will be demonstrated in detailed description of the invention.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to the formulation consisting of variable amounts of:
(i) micronized zeolite (MZ) of general formula:
Figure imgf000006_0001
wherein Me= Na, K, Mg, Ca, Fe, Zn, Mn, Cr; whereas ratio of silicon to aluminum, y:x is between 6:1 to 1 :1; number of crystalline water m is from 0 to 20, which is characterized by particles size < 5 μm; in concentrations from 1-50%, most preferably from 3-30%;
(ii) Green tea extract containing at least 30% of epigallocatechin gallate (EGCG; 1), and 5% of caffeine (2); in concentrations from 0.1-90%, most preferably from 20-90%;
Figure imgf000007_0001
1
(iii) genistein (3); in concentrations from 0.05-20%, most preferably from 1-10%;
Figure imgf000007_0002
and
(iv) one or more excipients which yield in desired pharmaceutical or cosmetic form: tablets, capsules, ointments, creams, gels, lotions, shampoos, powders, liquid powders, syrups, suspensions, and therapeutic patches; in concentrations from 1-98.85%, most preferably from 10-75%.
The formulation from the present invention provides highly effective reduction of body weight and cellulite.
We have been found that micronized zeolite clinoptilolite, or similar zeolites like zeolite A, when administered orally with Green tea extract and genistein surprisingly does act as very effective composition for treatment of obesity and cellulite.
In comparison to several persons of both sexes suffering from obesity, who consumed (3x2 cps/day) control capsules containing Green tea extract (390 mgs/cps) and genistein (50 mgs/cps), those consuming the formulation of the present invention in the form of the same kind of capsules (see Example 2) containing also micronized zeolite clinoptilolite (MZ; 50 mgs/cps) reached significantly greater reduction in body weight. In addition several female subjects during this study reported a profound reduction of intensity of cellulite condition. Moreover several women who used topical variant of the formulation of the present invention in the form of hydrophilic (O-W) cream containing 2% of micronized zeolite clinoptilolite (MZ), 2% of Green tea extract and 0.25% of genistein (see Example 4), also reported significant reduction of cellulite in comparison to women which used a control cream of the same composition but without MZ.
Possible mechanism of action
Silicon as essential microelement with a number of roles in human organism is biologically available in the form of ortho-silicic acid (H4SiO4). Among others, silicon acts as anti- inflammatoric in various conditions and diseases such as seborrheic dermatitis, neurodermitis, atopic dermatitis, skin irritations, disorders connected with decubitus, accelerates wound healing, and stimulates biosynthesis of skin building proteins collagen and elastin [C. D. Seaborn, F. H. Nielsen: Silicon deprivation decreases collagen formation in wounds and bone, and ornithine transaminase enzyme activity in liver, Biol. Trace Element Res. 89 (2002) 251; M. R. Calomme, D. A. V. Berghe: Supplementation of calves with stabilised orthosilicic acid effect on the Si, Ca, Mg and P concentration in serum and the collagen concentration in skin and cartilage, Biol. Trace Element Res. 56 (1997) 153].
Additionally, silicon takes a part in the structure of arterial, veins, and capillary walls; increases elasticity and hardness of blood vessels, and decreased their permeability [K. Schwartz: A bound form of silicon in glycosaminoglycans and polyuronides, Proc. Nat. Acad. Set USA 70 (1973) 1608; E. M. Carlisle, D. L. Garvey: The effect of silicon on formation of extra-cellular matrix components by chondrocytes in culture, Fed. Proc. 41 (1982) 461; E. M. Carlisle, C. Suchil: Silicon and ascorbate interaction in cartilage formation in culture, Fed. Proc. 42 (1983) 398].
Recently, we have described that micronized zeolite clinoptilolite (MZ) acts as effective pharmaceutically-acceptable source of highly bioavailable silicon. MZ is capable of releasing soluble silicon even in neutral water, presumably in the form of ortho-silicic acid, as demonstrated by quantitative analyses of aqueous supernatants obtained after trituration of MZ in pure redistilled water [Novatech, PCT7HR2008/000030].
Preparations and characterization of micronized zeolit clinoptilolite in all suitable pharmaceutical forms (Na+, K+, Mg2+, Ca2+, Fe2+/Fe3+, Zn2+, Mn2+, Cr3+) were performed in the same manner as shown in our mentioned previous application. Alternatively commercially available zeolite A can be used after micronization.
According to our best knowledge, herein described synergistic effect of micronized zeolite
(MZ) with Green tea extract and genistein in the treatment of obesity and cellulite conditions is a result of at least two possible mechanisms:
(i) Highly bioavailable silicon (from MZ) acts anti-inflammatorically what subsequently helps basic pharmacological actions of both EGCG (1) and caffeine (2; from Greefi tea extract) as well as of genistein (3); and
(ii) ortho-Silicic acid (from MZ) forms relatively stable complexes with ortho-diphenols like EGCG, and β-diketons or β-keto-enols (or analogous β-keto-phenols) such as genistein. In this manner it might enhance biological activity of these polyphenols by keeping their at sufficient concentrations in body fluids. This might occur due to decreased rate of their metabolism in liver through known polyphenols-elimination pathway by glucuronidation or sulfate-conjugation.
Composition of the formulation according to the invention
The formulation of the present invention is consisting of the mentioned components in the following concentrations:
(i) micronized zeolite (MZ) of general formula:
(Men+)x/π[(AlO2)x(SiO2)y]-mH2O (MZ)
wherein Me= Na, K, Mg, Ca, Fe, Zn, Mn, Cr; whereas ratio of silicon to aluminum, y:x is between 6:1 to 1 :1 ; number of crystalline water m is from 0 to 20, which is characterized by particles size < 5 μm; in concentrations from 1-50%, most preferably from 3-30%; (ii) Green tea extract containing at least 30% of epigallocatechin gallate (EGCG; 1), and 5% of caffeine (2); in concentrations from 0.1-90%, most preferably from 20-90%;
Figure imgf000010_0001
(iii) genistein (3); in concentrations from 0.05-20%, most preferably from 1-10%;
Figure imgf000010_0002
and
(iv) one or more excipients which yield in desired pharmaceutical or cosmetic form: tablets, capsules, ointments, creams, gels, lotions, shampoos, powders, liquid powders, syrups, suspensions, and therapeutic patches; in concentrations from 1-98.85%, most preferably from 10-75%.
Tablets, capsules, syrups, suspensions and therapeutic patches are preferred pharmaceutical forms for oral administration in treatment of obesity conditions, whereas forms such as ointments, creams, gels, lotions, shampoos, powders, liquid powders, and therapeutic patches are more suitable for topical treatment of cellulite.
Excipients are selected from the groups consisting of fillers, binders, disintegrants, lubricants, emollients, emulsifiers, tensides, humectants, solvents, thickeners, preservatives, antioxidants, stabilizers, and other functional additives which may help basic therapeutic action of above- defined main active substances. In solid dosage forms such as tablets, fillers are selected from the group consisting of microcrystalline cellulose, lactose monohydrate, calcium hydrogenphosphate, sorbitol, starch, modified starches, etc. As fillers in powders and liquid powders, the following substances can be used: talc, kaolin, bentonite, montmorillonite, precipitated calcium carbonate, basic magnesium carbonate, calcium silicate, aluminum hydroxide, silicon dioxide, or mixtures of these substances.
In solid dosage forms, binders are selected from the group consisting of gelatin, lactose monohydrate, sorbitol, saccharose, xylitol, maltitol, mannitol, starch, modified starches, methylcellulose, 2-hydroxyethylcellulose, 2-hydroxypropylcellulose, sodium carboxymethylcellulose, polyethyleneglycols, polyglycerols, polyvinylpyrrolidone, polyvinylpyrrolidone co-polymers, carrageenans, or mixtures of these substances.
Disintegrants in solid dosage forms are selected from the group consisting of starch, modified starches, sodium starch glycolate, methylcellulose, sodium carboxymethylcellulose, 2- hydroxyethylcellulose, 2-hydroxypropylcellulose, polyvinylpyrrolidone, polyvinylpyrrolidone co-polymers, or mixtures of these substances.
Lubricants in solid dosage forms and powders are selected from the group consisting of: metal soaps such as magnesium stearate, calcium stearate, and zinc stearate; higher fatty acids like stearic acid; talc; silicon dioxide; or mixtures of these substances.
Emollients in semi-solid and liquid forms of the formulation for topical treatment of cellulite such as ointments, creams, and lotions, are selected from the group consisting of: paraffin wax; mineral oil; petroleum jelly; ozokerite; synthetic esters of higher fatty acids like isopropyl myristate, isopropyl palmitate, trimethylolpropane tristearate, glyceryl tricaprylate; natural waxes such as beeswax or spermaceti; liquid natural waxes such as jojoba oil; synthetic waxes such as lauryl laurate; plant oils such as soybean oil, sweet almond oil, sunflower seed oil, fish oil, olive oil, wheat germ oil, corn germ oil, avocado oil, palm oil, coconut oil; semi-solid or liquid silicones; higher fatty alcohols such as cetyl alcohol, stearyl alcohol, oleyl alcohol; or mixtures of these substances. Emulsifiers in creams, ointments, and other forms of the formulation such as lotions and shampoos, are selected from the group consisting of: metal salts of sulphates of higher fatty alcohols like sodium laurylsulphate, sodium lauryl ethyleneglycolsulphate, sodium lauryl diethyleneglycolsulphate; ethoxylates of higher fatty alcohols such as polyoxyethylene(2) laurylether, polyoxyethylene(lθ) laurylether, polyoxyethylene(23) laurylether, and others, where 2, 10 and 23 represent average number of ethyleneglycol units bounded on higher fatty alcohol; ethoxylates of higher fatty acids such as polyoxyethylene(2) laurate, polyoxyethylene(lθ) laurate, polyoxyethylene(23) laurate, and others, wherein 2, 10 and 23 represent average number of ethyleneglycol units bounded on higher fatty acid; esters of sorbitan such as polyoxyethylene sorbitan monolaurate; lanolin; ethoxylated lanolins; glyceryl monostearate; beeswax ethoxylates; or mixtures of these substances.
Tensides in liquid forms of the formulation like shampoos, are selected from the group consisting of: metal salts of sulphates of higher fatty alcohols such as sodium laurylsulphate, sodium lauryl ethyleneglycolsulphate, sodium lauryl diethyleneglycolsulphate, potassium laurylsulphate, potassium lauryl ethyleneglycolsulphate, potassium lauryl diethyleneglycolsulphate, ammonium laurylsulphate, ammonium lauryl ethyleneglycolsulphate, ammonium lauryl diethyleneglycolsulphate, sodium or potassium cocoamphodipropionate; disodium or dipotassium cocoamphodiacetate; polyoxyethylene(lθ) laurylether, polyoxyethylene(23) laurylether, polyoxyethylene(lθ) stearylether, polyoxyethylene(23) stearylether, polyoxyethylene(lθ) oleylether, polyoxyethylene(23) oleylether, and other ethoxylates of higher fatty alcohols with H.L.B. value >10; polyoxyethylene(lθ) laurate, polyoxyethylene(23) laurate, polyoxyethylene(lθ) stearate, polyoxyethylene(23) stearate, polyoxyethylene(lθ) oleate, polyoxyethylene(23) oleate; or other ethoxylates of higher fatty acids with H.L.B. value >10; esters of sorbitan such as polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monooleate, or other sorbitan derivatives with H.L.B. value >10; mono- or diethanolamides of higher fatty acids; cocoamidopropyl betaine; glycosides of higher fatty alcohols like cocoglucoside; sodium or potassium di(2-ethylhexyl)sulfosuccinate; disodium or dipotassium 2-ethylhexylsulfosuccinate; cationic tensides such as cetyltrimethylammonium bromide, didecyldimethylammonium chloride, benzalkonium chloride, cetylbenzyldimethylammonium bromide, cetylpyridinium chloride; metal salts of higher fatty acids such as sodium or potassium salts of lauric, myristic, palmitic, stearic, oleic, or ricinoleic acid; or mixtures of these substances.
Humectants are selected from the group consisting of glycerol, 1 ,2-propyleneglycol, 1,3- propyleneglycol, hexyleneglycol, 1,3-butanediol, polyethyleneglycols, polyglycerols, sorbitol, xylitol, saccharose, urea, sodium hyaluronate, or mixtures of these substances.
Solvents in liquid forms of the formulation like lotions are selected from the group consisting of purified water, ethanol, 1-propanol, isopropanol, isosorbide dimethylether, diethyleneglycol monomethylether, diethyleneglycol dimethylether, diethyleneglycol monoethylether, diethyleneglycol diethylether, triethyleneglycol monomethylether, triethyleneglycol dimethylether, triethyleneglycol monoethylether, triethyleneglycol diethylether, ethyl lactate or other lactate esters with lower aliphatic alcohols, triethylhexanoin, or mixtures of these substances.
Thickeners in the formulation are selected from the group consisting of: polyacrylic acid, its co-polymers, or their sodium, potassium, or triethanolamine salts; methylcellulose; sodium carboxymethylcellulose; 2-hydroxyethylcellulose; 2-hydroxypropylcellulose; starch; modified starches; polyglycerols; polyethyleneglycols; gelatin; pectin; agar agar; carrageenans; gum arabic; alginic acid; sodium alginate; montmorillonite; bentonite; or mixtures of these substances.
Preservatives are selected from the group consisting of: methyl 4-hydroxybenzoate; ethyl 4- hydroxybenzoate; propyl 4-hydroxybenzoate; butyl 4-hydroxybenzoate; triclosan; chlorhexidine or its dihydrochloride, diacetate, or digluconate salts; sorbic acid; potassium sorbate; benzoic acid; sodium benzoate; 2-bromo-2-nitropropane-l,3-diol; 2- hydroxybiphenyl; 2-phenoxyethanol; 4-chloro-m-cresol; thymol; eugenol; methyl salicylate; or mixtures of these substances.
Antioxidants are selected from the group consisting of 2,6-di-terc-butyl-4-hydroxytoluene (BHT), terc-butylhydroxyanisole (BHA), tocopherol, tocopherol acetate, ascorbic acid, ascorbyl palmitate, or mixtures of these substances. Stabilizers are selected from the group consisting of disodium ethylenediamine tetraacetate (Na2EDTAx2H2O), disodium N-(2-hydroxyethyl)ethylenediamine triacetate
[Na2H(HEDTA)], disodium diethylenetriamine pentaacetate [Na2H3(DTPA)], disodium citrate [Na2(C(OH)(COOH)(CH2COO)2], or mixtures of these substances.
It is well known to those skilled in the art that several mentioned excipients can play two-or- more roles in the formulation of the present invention. Therefore numerous combinations are possible but still remain within the scope of this invention.
Other functional additives which may help basic therapeutic action of above-defined main active substances are selected from the group known to those skilled in the art as anti- inflammatory and/or antiphlogistic agent, antioxidant, astringent, and various skin tonifying agents.
Anti-inflammatory and/or antiphlogistic agent is selected from the group consisting of: paracetamol; metamizol sodium; acetylsalicylic acid and its salts with pharmaceutically acceptable bases; salicylic acid and its salts with pharmaceutically acceptable bases; salsalate; methyl salicylate; ethyl salicylate; benzyl salicylate; 2-hydroxyethyl salicylate; salicylamide; phenylbutazone sodium; propyphenazone; oxyphenbutazone; mofebutazone; bumadizon calcium; phenazone; ethenzamide; ketoprofen, ibuprofen, naproxen, flurbiprofen, pirprofen, mefenamic acid, fluphenamic acid, thiaprofenic acid or their salts with pharmaceutically acceptable bases; diclofenac sodium; indomethacin; piroxicam; meloxicam; codeine; caffeine; extract of St John's wort (Hypericum perforatum); azulene; extract of Chamomile (Matricaria recutita); extract of Marigold (Calendula officinalis); extract of Arnica (Arnica montana); extract of White Willow (Salix alba); extract of Spiny Restharrow (Ononis spinosa); menthol; essential oil or extract of Mint (Mentha piperita); eucalyptol; essential oil or extract of Rosemary (Rosmarinus officinalis); essential oil or extract of Lavender (Lavandula officinalis); purified turpentine oil; camphor; pinene; bornyl acetate; terpineol; terpenyl acetate; eugenol; essential oil of Lemon (Citrus limonum); essential oil of Orange (Citrus aurantium); essential oil of Common Juniper (Juniperus communis); essential oil of Clove (Syzygium aromaticum); extract of Green Tea (Camellia sinensis); extract of Rooibos (Aspalathus linearis); extract of Nettle (Urtica dioica); extract of Horse-Chestnut (Aesculus hippocastanum); extract of Mullein (Verbascum phlomoides); extract of European Holly (Ilex aquifolium); extract of Borage (Borago officinalis); extract of Burdock (Arctium lappa); extract of Ribwort Plantain (Plantago lanceolata); extract of Century Plant (Agave americana); extract of Ground Pine (Lycopodium clavatum); methyl nicotinate; benzyl nicotinate; glucosamine sulfate; L-histidine; chondroitin sulfate; hyaluronidase; heparin sodium; coumarin; choline and its salts; sulphur; extracts of plants with significant content of silicic acid (H4SiO4) such as Field Horsetail (Equisetum arvense), Lungwort (Pulmonaria officinalis), Common Knotgrass (Polygonum aviculare), Couch Grass (Agropyron repens), Common Agrimony (Agrimonia eupatoria), Oat (Avena sativa); cortisone; hydrocortisone; dexamethasone; betamethasone; alclometasone; fluprednidene; prednisone; prednisolone; triamcinolone; methylprednisolone; paramethasone; clobetasol; diflorasone; fluocinolone; clocortolone; flumetasone; halometasone; fluocortolone; diflucortolone; mono- or diesters of mentioned synthetic steroids at 17- and/or 21 -positions, or 16,17-acetonide derivatives such as hydrocortisone acetate, hydrocortisone- 17-butyrate, betamethasone- 17-valerate, betamethasone- 17,21 -dipropionate, alclometasone- 17,21 -dipropionate, triamcinolone- 16α,17α-acetonide; or mixtures of these substances.
Antioxidant is selected from the group consisting of: extract of Rooibos (Aspalathus linearis); extract of Nettle (Urtica dioica); extract of Bilberry (Vaccinium myrtillus); extract of Orange (Citrus aurantium); silymarin; extract of Milk Thistle (Silybum marianum); ascorbic acid, its salts, and esters such as ascorbyl palmitate; tocoferol; tocoferol acetate; niacinamide; rutin; quercetin; extracts of plants with significant content of rutin and/or quercetin; cyanidin; hesperidin; diosmin; lycopene; extracts of plants with significant contents of lycopene; resveratrol; tetrahydrocurcumin; rosmarinic acid; extract of Rosemary (Rosmarinus officinalis); hypericin; extract of St John's wort (Hypericum perforatum); ellagic acid; chlorogenic acid; 3,4-dihydroxycinnamic acid; oleuropein; extract of Olive leaves (Olea europea); extract of Grape seed; pycnogenol; carnosine; α-lipoic acid; glutathione; extracts of plants with significant content of silicic acid (H4SiO4) such as Field Horsetail (Equisetum arvense), Lungwort (Pulmonaria officinalis), Common Knotgrass (Polygonum aviculare), Couch Grass (Agropyron repens), Common Agrimony (Agrimonia eupatoria), Oat (Avena sativa), Silverweed (Potentilla anserina), Common Bistort (Polygonum bistorta), Common Sage (Salvia officinalis); or mixtures of these substances. Astringent is selected from the group consisting of: zinc oxide; zinc stearate; zinc tannate; zinc acetate; zinc sulphate; zinc chloride; iron(III) chloride; aluminum sulphate; potassium aluminum sulphate; aqueous basic aluminum acetate; aluminum acetotartarate; bismuth subnitrate; bismuth subcarbonate; bismuth phosphate; bismuth tannate; calamine; copper(II) sulphate; silver nitrate; silver-proteine; aescin; extract of Horse-Chestnut (Aesculus hippocastanum); Balsam of Peru; silica gel; kaolin; talc; titanium dioxide; tannic acid; albumin tannate; methylene ditannate; extracts with significant content of tannins such as extracts of Oak bark (Cortex Quercus ruber, Quercus sessiliflora), Bearberry leaves (Arctostaphylos uvae ursϊ), Common Agrimony (Agrimonia eupatoria), Silverweed (Potentilla anserinά), Common Bistort (Polygonum bistrota), Common Sage (Salvia officinalis), etc.; or compatible mixtures of these substances.
Skin tonifying agents are selected from the group consisting of: vitamins and pro-vitamins like retinol palmitate, β-carotene, niacinamide, d-panthenol, calcium pantothenate, folic acid, riboflavin, pyridoxine, thiamine, biotin, cyanocobalamin, ascorbic acid its salts and esters such as ascorbyl palmitate, cholecalciferol, tocopherol, tocopherol acetate, phylloquinone, menaquinone, menadione; animal and plant oils with high contents of omega-3 higher fatty acids such as fish or linseed oil; choline chloride; protein hydrolysates; algae extracts; extract of Witch-hazel (Hamamelis virginiana); extract of Centaurium (Erythraea centaurum); extract of Mullein (Verbascum phlomoides); extract of European Holly (Ilex aquifolium); extract of Common Ivy (Hedera helix); chlorophyll; α-hydroxyacids like glycolic, lactic, malic, citric, and tartaric acid; urea; co-enzyme QlO; or mixtures of these substances.
The formulation of the present invention can be in the form of tablets, capsules, ointments, creams, gels, lotions, shampoos, powders, liquid powders, syrups, suspensions, and therapeutic patches. The formulations are produced by common procedures known to those skilled in the art of cosmetic and/or pharmaceutical technology [S. C. Gad (Ed.): Pharmaceutical Manufacturing Handbook: Production and Processes, Wiley (2008)]. Several possible variations are possible but which essentially remain under the scope of this invention. EXAMPLES
General information
Preparations and characterizations of micronized zeolite (MZ) in all possible forms (Na, K, Mg, Ca, Fe, Zn, Mn, Cr) were carried out in our R&D department according to procedures previously described in our recent patent application [Novatech, PCT/HR2008/000030]. Zeolite A and natural clinoptilolite were purchased and micronized in our laboratory. The term room temperature means: 20-25 0C.
Example 1
Preparation of the formulation in the form of 1000 mg tablets for reduction of body weight
Content (100 g of tablet mixture): (a) Micronized zeolite A (MZ; 10.00 g; 10%), (b) Green tea extract (40.00 g; 40%), (c) genistein (3; 10.00 g; 10%), (d) microcrystalline cellulose (15.00 g; 15%), (e) lactose monohydrate (20.00 g; 20%), (f) sodium starch glycolate (2.00 g; 2%), (g) polyvinylpyrrolidone (2.00 g; 2%), (h) magnesium stearate (1.00 g; 1%).
Procedure: Ingredients (a), (b), (c), (d), (e), (f) and (g) were homogenized in dry homogenizer during 15 minutes. Then, (h) was added and homogenization was continued for 15 minutes. Then, homogeneous mixture was milled, and compressed into tablets yielding approx. 100 tablets (1000 mg). Average tablet weight 993 mg.
Example 2
Preparation of the formulation in the form of capsules for reduction of body weight
Content (1000 g of capsules mixture): (a) Micronized zeolite clinoptilolite (MZ; natural, 100.00 g; 10%), (b) Green tea extract (740.00 g; 74%), (c) genistein (3; 100.00 g; 10%), (d) microcrystalline cellulose (50.00 g; 5%), (e) magnesium stearate (10.00 g; 1%). Procedure: Previously milled ingredients (a), (b), (c), and (d) were homogenized in a homogenizer during 15 minutes. Then milled (e) was added and homogenization was continued for 15 minutes. Then the homogeneous mixture was capsulated into hard-gelatine capsules ("0") using a laboratory capsule filling machine yielding approx. 1850 cps. Average weight of capsules: 620 mgs brutto; 530 mgs netto.
Composition per cps: 50 mgs of genistein; 390 mgs of Green tea extract (corresponds to 175 mgs of EGCG and 40 mgs of caffeine); and 50 mgs of micronized clinoptilolite.
Example 3
Preparation of the formulation in the form of a syrup for reduction of body weight
Content (100 g of syrup): (a) Micronized zeolite clinoptilolite (MZ; Ca-form, 5.00 g; 5%), (b) Green tea extract (5.00 g; 5%), (c) genistein (3; 1.00 g; 1%), (d) sorbitol (70% solution in water; 60.00 g; 60%), (e) xylitol (1.00 g; 1%), (f) 1 ,2-propyleneglycol (10.00 g; 10%), (g) methyl cellulose (Ph. Eur. grade; 0.30 g; 0.3%), (h) methyl 4-hydroxybenzoate (0.20 g; 0.2%), (i) ethanol (0.60 g; 0.6%), 0) artificial strawberry arome (1.00 g; 1.0%); (k) purified water (15.90 g; 15.9%).
Procedure: Ingredient (g) was slowly added into previously prepared mixture of (d), (f), and (k) and vigorously stirred for 2 hrs. Then (a), (b), (c), (e), and (j) were added and homogenization was continued for 30 minutes. Then, separately prepared solution of (h) in (i) was added, and finally homogenized for 15 minutes, giving 100 gms of strawberry-coloured viscous syrup.
Example 4
Preparation of the formulation in the form of a cream for topical treatment of cellulite
Content (100 g of cream): (a) Petroleum jelly (18.00 g; 18%), (b) cetyl alcohol (16.00 g; 16%), (c) lanolin (2.00 g; 2%), (d) isopropyl myristate (2.00 g; 2%), (e) sodium laurylsulphate (1.00 g; 1%), (f) methyl 4-hydroxybenzoate (0.10 g; 0.1%), (g) ethyl 4-hydroxybenzoate (0.05 g; 0.05%), (h) propyl 4-hydroxybenzoate (0.025 g; 0.025%), (i) butyl 4-hydroxybenzoate (0.025 g; 0.025%), G) sorbitol (7.00 g; 7%), (k) glycerol (3.00 g; 3%), (1) micronized zeolite clinoptilolite (MZ; natural; 2.00 g; 2%), (m) Green tea extract (2.00 g; 2%), (n) genistein (3; 0.25 g; 0.25%), (o) isosorbide dimethylether (1.00 g; 1%), (p) purified water (44.75 g; 44.75%), (q) fragrance (0.80 g; 0.8%).
Procedure: Ingredients (a) and (b) were carefully melted, and further heated to 80 0C with stirring. Then (c), (d), (e), (f), (g), (h), and (i) were added. The mixture was stirred at this temperature for 30 min. Water phase was prepared by dissolution of (j) and (k) in (p), and added drop- wise during 30 min into hot fatty-phase with vigorous stirring. Thus obtained emulsion was further stirred at temperatures between 80 0C and 50 0C during additional 30 minutes, and then (o), (1), (m), (n), and (q) were added. The cream was stirred at 50 0C for 30 minutes, and then carefully cooled to room temperature with constant stirring. The product was additionally homogenized by mixing at room temperature during 15 min. The product was orange-brown, fine, semi-solid cream with slight scent of fragrance employed.
Example S
Preparation of the formulation in the form of an ointment for topical treatment of cellulite
Content (100 g of ointment): (a) Petroleum jelly (40.00 g; 40%), (b) heavy mineral oil (21.10 g; 21.1%), (c) soyben oil (20.00 g; 20%), (d) sweet almond oil (10.00 g; 10%), (e) yellow beeswax (0.30 g; 0.3%), (f) micronized zeolite clinoptilolite (MZ; Ca-form; 3.00 g; 3%), (g) Green tea extract (3.00 g; 3%), (h) genistein (3; 0.50 g; 0.5%), (i) isosorbid dimethylether (1.00 g; 1%), G) d-panthenol (0.25 g; 0.25%), (k) tocoferol acetate (0.10 g; 0.1%), (1) lavender oil (0.75 g; 0.75%).
Procedure: Ingredients (b), (c), and (d) were slowly heated to 60 0C, and then (a) and (e) were added with stirring until clear oily liquid was formed. Then (f), (g), (h), (i), G)5 (k), and (1) were added, and stirring was continued for 15 minutes. Thus obtained mixture was carefully poured into small (25 mL) plastic jars. The product was in the form of fine, slightly orange- brown, semi-solid ointment of agreeable lavender scent. Example 6
Preparation of the formulation in the form of a gel for topical treatment of cellulite
Content (100 g of gel): (a) 1 ,2-Propyleneglycol (25.00 g; 25%), (b) glycerol (3.00 g; 3%), (c) sorbitol (70% solution in water; 5.00 g; 5%), (d) ethanol (96%; 10.00 g; 10%), (e) Carbopol 934P (1.00 g; 1%), (f) triethanolamine (q.s.), (g) micronized zeolite clinoptilolite (MZ; Mg- form; 3.00 g; 3%), (h) Green tea extract (2.00 g; 2%), (i) genistein (3; 0.2 g; 0.2%), G) methyl 4-hydroxybenzoate (0.15 g; 0.15%), (k) propyl 4-hydroxybenzoate (0.05 g; 0.05%), (1) purified water (49.10 g; 49.1%), (m) mixture of essential oils of lemon and cinnamon (2:1 w/w; 1.5O g; 1.5%).
Procedure: To vigorously stirred (1), (e) was added in small portions over 15 minutes. Obtained mixture was stirred at room temperature during 2 h giving clear colourless viscous liquid. Then other ingredients were added in the following order: (a), (b), (c), (d), (g), (h), (i), (j), and (k), and the mixture was stirred at room temperature for additional 30 minutes. Then (m) was added and stirred for 10 minutes, followed by (f) until the pH between 6-6.5 was reached, and mixed until the formation of orange-brown turbid gel of fine top-lemon, cinnamon-undertone scent. Finally the product was homogenized by stirring at room temperature for 15 minutes.
Example 7
Efficacy of capsule form of the formulation in reduction of body weight
Several persons of both sexes suffering from obesity were consumed (3x2 cps/day) control capsules containing Green tea extract (390 mgs/cps) and genistein (50 mgs/cps). Those persons which consumed the formulation of the present invention in the form of capsules containing, beside mentioned active substances, also micronized zeolite clinoptilolite (MZ; 50 mgs/cps) reached significantly greater and faster reduction in body weight.
In addition several female subjects during this study reported a profound decreasing of cellulite. Example 8
Efficacy of cream form of the formulation for the topical treatment of cellulite
Several women which used the topical variant of the formulation of the present invention in the form of hydrophilic (O- W) cream containing 2% of micronized zeolite clinoptilolite (MZ), 2% of Green tea extract and 0.25% genistein (see Example 4), reported significant reduction of intensity of cellulite appearance in comparison to women which used a control cream of the same composition but without MZ.

Claims

1. The formulation based on micronized zeolite (MZ) as therapeutic agent for reduction of body weight and cellulite, characterised by the variable portions of:
(i) micronized zeolite (MZ) of general formula:
(MenV[(AlO2)x(SiO2)y]«wH2O (MZ)
wherein Me= Na, K, Mg, Ca, Fe, Zn, Mn, Cr; whereas ratio of silicon to aluminum, y:x is between 6:1 to 1 :1; number of crystalline water m is from 0 to 20, which is characterized by particles size < 5 μm; in concentrations from 1-50%, most preferably from 3-30%;
(ii) Green tea extract containing at least 30% of epigallocatechin gallate (EGCG; 1), and 5% of caffeine (2); in concentrations from 0.1-90%, most preferably from 20-90%;
Figure imgf000022_0001
(iii) genistein (3); in concentrations from 0.05-20%, most preferably from 1-10%;
Figure imgf000022_0002
and (iv) one or more excipients which yield in desired pharmaceutical or cosmetic form: tablets, capsules, ointments, creams, gels, lotions, shampoos, powders, liquid powders, syrups, suspensions, and therapeutic patches; in concentrations from 1-98.85%, most preferably from 10-75%.
2. Formulation according to claim 1, characterized by that the excipients are selected from the groups consisting of fillers, binders, disintegrants, lubricants, emollients, emulsifϊers, tensides, humectants, solvents, thickeners, preservatives, antioxidants, stabilizers, and other functional additives which may help basic therapeutic action of main active substances.
3. Formulation according to claims 1 and 2, characterized by that the excipient is filler selected from the group consisting of microcrystalline cellulose, lactose monohydrate, calcium hydrogenphosphate, sorbitol, starch, modified starches, talc, kaolin, bentonite, montmorillonite, precipitated calcium carbonate, basic magnesium carbonate, calcium silicate, aluminum hydroxide, silicon dioxide, or mixtures of these substances.
4. Formulation according to claims 1-3, characterized by that the excipient is binder selected from the group consisting of gelatin, lactose monohydrate, sorbitol, saccharose, xylitol, maltitol, mannitol, starch, modified starches, methylcellulose, 2-hydroxyethylcellulose, 2- hydroxypropylcellulose, sodium carboxymethylcellulose, polyethyleneglycols, polyglycerols, polyvinylpyrrolidone, polyvinylpyrrolidone co-polymers, carrageenans, or mixtures of these substances.
5. Formulation according to claims 1-4, characterized by that the excipient is disintegrant selected from the group consisting of starch, modified starches, sodium starch glycolate, methylcellulose, sodium carboxymethylcellulose, 2-hydroxyethylcellulose, 2- hydroxypropylcellulose, polyvinylpyrrolidone, polyvinylpyrrolidone co-polymers, or mixtures of these substances.
6. Formulation according to claims 1-5, characterized by that the excipient is lubricant selected from the group consisting of: metal soaps such as magnesium stearate, calcium stearate, zinc stearate; higher fatty acids such as stearic acid; talc; silicon dioxide; or mixtures of these substances.
7. Formulation according to claims 1-6, characterized by that the excipient is emollient selected from the group consisting of: paraffin wax; mineral oil; petroleum jelly; ozokerite; synthetic esters of higher fatty acids like isopropyl myristate, isopropyl palmitate, trimethylolpropane tristearate, glyceryl tricaprylate; natural waxes such as beeswax or spermaceti; liquid natural waxes such as jojoba oil; synthetic waxes such as lauryl laurate; plant oils such as soybean oil, sweet almond oil, sunflower seed oil, fish oil, olive oil, wheat germ oil, corn germ oil, avocado oil, palm oil, coconut oil; semi-solid or liquid silicones; higher fatty alcohols such as cetyl alcohol, stearyl alcohol, oleyl alcohol; or mixtures of these substances.
8. Formulation according to claims 1-7, characterized by that the excipient is emulsifier selected from the group consisting of: metal salts of sulphates of higher fatty alcohols like sodium laurylsulphate, sodium lauryl ethyleneglycolsulphate, sodium lauryl diethyleneglycolsulphate; ethoxylates of higher fatty alcohols such as polyoxyethylene(2) laurylether, polyoxyethylene(lθ) laurylether, polyoxyethylene(23) laurylether, and others, where 2, 10 and 23 represent average number of ethyleneglycol units bounded on higher fatty alcohol; ethoxylates of higher fatty acids such as polyoxyethylene(2) laurate, polyoxyethylene(lθ) laurate, polyoxyethylene(23) laurate, and others, wherein 2, 10 and 23 represent average number of ethyleneglycol units bounded on higher fatty acid; esters of sorbitan such as polyoxyethylene sorbitan monolaurate; lanolin; ethoxylated lanolins; glyceryl monostearate; beeswax ethoxylates; or mixtures of these substances.
9. Formulation according to claims 1-8, characterized by that the excipient is tenside selected from the group consisting of: metal salts of sulphates of higher fatty alcohols such as sodium laurylsulphate, sodium lauryl ethyleneglycolsulphate, sodium lauryl diethyleneglycolsulphate, potassium laurylsulphate, potassium lauryl ethyleneglycolsulphate, potassium lauryl diethyleneglycolsulphate, ammonium laurylsulphate, ammonium lauryl ethyleneglycolsulphate, ammonium lauryl diethyleneglycolsulphate, sodium or potassium cocoamphodipropionate; disodium or dipotassium cocoamphodiacetate; polyoxyethylene(lθ) laurylether, polyoxyethylene(23) laurylether, polyoxyethylene(lθ) stearyl ether, polyoxyethylene(23) stearylether, polyoxyethylene(lθ) oleylether, polyoxyethylene(23) oleyl ether, and other ethoxylates of higher fatty alcohols with H. L. B. value >10; polyoxyethylene(lθ) laurate, polyoxyethylene(23) laurate, polyoxyethylene(lθ) stearate, polyoxyethylene(23) stearate, polyoxyethylene(lθ) oleate, polyoxyethylene(23) oleate; or other ethoxylates of higher fatty acids with H. L. B. value >10; esters of sorbitan such as polyoxyethylene sorbitan monolaurate, polyoxyethylene sorbitan monostearate, polyoxyethylene sorbitan monooleate, or other sorbitan derivatives with H.L.B. value >10; mono- or diethanolamides of higher fatty acids; cocoamidopropyl betaine; glycosides of higher fatty alcohols like cocoglucoside; sodium or potassium di(2-ethylhexyl)sulfosuccinate; disodium or dipotassium 2-ethylhexylsulfosuccinate; cationic tensides such as cetyltrimethylammonium bromide, didecyldimethylammonium chloride, benzalkonium chloride, cetylbenzyldimethylammonium bromide, cetylpyridinium chloride; metal salts of higher fatty acids such as sodium or potassium salts of lauric, myristic, palmitic, stearic, oleic, or ricinoleic acid; or mixtures of these substances.
10. Formulation according to claims 1-9, characterized by that the excipient is humectant selected from the group consisting of glycerol, 1 ,2-propyleneglycol, 1,3-propyleneglycol, hexyleneglycol, 1,3-butanediol, polyethyleneglycols, polyglycerols, sorbitol, xylitol; saccharose, urea, sodium hyaluronate, or mixtures of these substances.
11. Formulation according to claims 1-10, characterized by that the excipient is solvent selected from the group consisting of purified water, ethanol, 1-propanol, isopropanol, isosorbide dimethylether, diethyleneglycol monomethylether, diethyleneglycol dimethylether, diethyleneglycol monoethylether, diethyleneglycol diethylether, triethyleneglycol monomethylether, triethyleneglycol dimethylether, triethyleneglycol monoethylether, triethyleneglycol diethylether, ethyl lactate or other lactate esters with lower aliphatic alcohols, triethylhexanoin, or mixtures of these substances.
12. Formulation according to claim 1-11, characterized by that the excipient is thickener selected from the group consisting of: polyacrylic acid, its co-polymers, or their sodium, potassium, or triethanolamine salts; methylcellulose; sodium carboxymethylcellulose; 2- hydroxyethylcellulose; 2-hydroxypropylcellulose; starch; modified starches; polyglycerols; polyethyleneglycols; gelatin; pectin; agar agar; carrageenans; gum arabic; alginic acid; sodium alginate; montmorillonite; bentonite; or mixtures of these substances.
13. Formulation according to claims 1-12, characterized by that other functional additives which help basic therapeutic action of main active substances are selected from the group consisting of anti-inflammatory and/or antiphlogistic agent, antioxidant, astringent, and skin tonifying agent, or mixtures of these substances.
14. Formulation according to claims 1-13, characterized by that other functional additive which helps basic therapeutic action of main active substances is anti-inflammatory and/or antiphlogistic agent selected from the group consisting of: paracetamol; metamizol sodium; acetylsalicylic acid and its salts with pharmaceutically acceptable bases; salicylic acid and its salts with pharmaceutically acceptable bases; salsalate; methyl salicylate; ethyl salicylate; benzyl salicylate; 2-hydroxyethyl salicylate; salicylamide; phenylbutazone sodium; propyphenazone; oxyphenbutazone; mofebutazone; bumadizon calcium; phenazone; ethenzamide; ketoprofen, ibuprofen, naproxen, flurbiprofen, pirprofen, mefenamic acid, fiuphenamic acid, thiaprofenic acid or their salts with pharmaceutically acceptable bases; diclofenac sodium; indomethacin; piroxicam; meloxicam; codeine; caffeine; extract of St John's wort {Hypericum perforatum); azulene; extract of Chamomile {Matricaria recutita); extract of Marigold {Calendula officinalis); extract of Arnica {Arnica montana); extract of White Willow {Salix alba); extract of Spiny Restharrow {Ononis spinosa); menthol; essential oil or extract of Mint {Mentha piperita); eucalyptol; essential oil or extract of Rosemary {Rosmarinus officinalis); essential oil or extract of Lavender {Lavandula officinalis); purified turpentine oil; camphor; pinene; bornyl acetate; terpineol; terpenyl acetate; eugenol; essential oil of Lemon {Citrus limonum); essential oil of Orange {Citrus aurantium); essential oil of Common Juniper {Juniperus communis); essential oil of Clove {Syzygium aromaticum); extract of Green Tea {Camellia sinensis); extract of Rooibos {Aspalathus linearis); extract of Nettle {Urtica dioica); extract of Horse-Chestnut {Aesculus hippocastanum); extract of Mullein {Verbascum phlomoides); extract of European Holly {Ilex aquifolium); extract of Borage {Borago officinalis); extract of Burdock {Arctium lappa); extract of Ribwort Plantain {Plantago lanceolata); extract of Century Plant {Agave americana); extract of Ground Pine {Lycopodium clavatum); methyl nicotinate; benzyl nicotinate; glucosamine sulfate; L-histidine; chondroitin sulfate; hyaluronidase; heparin sodium; coumarin; choline and its salts; sulphur; extracts of plants with significant content of silicic acid (H4SiO4) such as Field Horsetail {Equisetum arvense), Lungwort (Pulmonaria officinalis), Common Knotgrass (Polygonum aviculare), Couch Grass (Agropyron repens), Common Agrimony {Agrimonia eupatoria), Oat {Avena sativa); cortisone; hydrocortisone; dexamethasone; betamethasone; alclometasone; fluprednidene; prednisone; prednisolone; triamcinolone; methylprednisolone; paramethasone; clobetasol; diflorasone; fluocinolone; clocortolone; flumetasone; halometasone; fluocortolone; diflucortolone; mono- or diesters of mentioned synthetic steroids at 17- and/or 21 -positions, or 16,17-acetonide derivatives such as hydrocortisone acetate, hydrocortisone- 17-butyrate, betamethasone- 17-valerate, betamethasone- 17,21- dipropionate, alclometasone- 17,21 -dipropionate, triamcinolone- 16α,17α-acetonide; or mixtures of these substances.
15. Formulation according to claims 1-14, characterized by that other functional additive which helps basic therapeutic action of main active substances is antioxidant selected from the group consisting of: extract of Rooibos {Aspalathus linearis); extract of Nettle {Urtica dioica); extract of Bilberry {Vaccinium myrtillus); extract of Orange {Citrus aurantium); silymarin; extract of Milk Thistle (Silybum marianum); ascorbic acid, its salts, and esters such as ascorbyl palmitate; tocoferol; tocoferol acetate; niacinamide; rutin; quercetin; extracts of plants with significant content of rutin and/or quercetin; cyanidin; hesperidin; diosmin; lycopene; extracts of plants with significant contents of lycopene; resveratrol; tetrahydrocurcumin; rosmarinic acid; extract of Rosemary {Rosmarinus officinalis); hypericin; extract of St John's wort {Hypericum perforatum); ellagic acid; chlorogenic acid; 3,4-dihydroxycinnamic acid; oleuropein; extract of Olive leaves {Olea europea); extract of Grape seed; pycnogenol; carnosine; α-lipoic acid; glutathione; extracts of plants with significant content of silicic acid (H4SiO4) such as Field Horsetail {Equisetum arvense), Lungwort {Pulmonaria officinalis), Common Knotgrass (Polygonum aviculare), Couch Grass {Agropyron repens), Common Agrimony {Agrimonia eupatoria), Oat {Avena sativa), Common Agrimony {Agrimonia eupatoria), Silverweed {Potentilla anserina), Common Bistort {Polygonum bistorta), Common Sage {Salvia officinalis); or mixtures of these substances.
16. Formulation according to claims 1-15, characterized by that other functional additive which helps basic therapeutic action of main active substances is astringent selected from the group consisting of: zinc oxide; zinc stearate; zinc tannate; zinc acetate; zinc sulphate; zinc chloride; iron(III) chloride; aluminum sulphate; potassium aluminum sulphate; aqueous basic aluminum acetate; aluminum acetotartarate; bismuth subnitrate; bismuth subcarbonate; bismuth phosphate; bismuth tannate; calamine; copper(II) sulphate; silver nitrate; silver-proteine; aescin; extract of Horse-Chestnut (Aesculus hippocastanum); Balsam of Peru; silica gel; kaolin; talc; titanium dioxide; tannic acid; albumin tannate; methylene ditannate; extracts with significant content of tannins such as extracts of Oak bark {Cortex Quercus ruber, Quercus sessiliflora), Bearberry leaves (Arctostaphylos uvae ursϊ), Common Agrimony (Agrimonia eupatoria), Silverweed (Potentilla anserina), Common Bistort {Polygonum bistrota), Common Sage {Salvia officinalis); or mixtures of these substances.
17. Formulation according to claims 1-16, characterized by that other functional additive which helps basic therapeutic action of main active substances is skin tonifying agent selected from the group consisting of: vitamins and pro-vitamins like retinol palmitate, β- carotene, niacinamide, d-panthenol, calcium pantothenate, folic acid, riboflavin, pyridoxine, thiamine, biotin, cyanocobalamin, ascorbic acid its salts and esters such as ascorbyl palmitate, cholecalciferol, tocopherol, tocopherol acetate, phylloquinone, menaquinone, menadione; animal and plant oils with high contents of omega-3 higher fatty acids such as fish or linseed oil; choline chloride; protein hydrolysates; algae extracts; extract of Witch-hazel {Hamamelis virginiana); extract of Centaurium {Erythraea centaurum); extract of Mullein {Verbascum phlomoides); extract of European Holly {Ilex aquifolium); extract of Common Ivy {Hedera helix); chlorophyll; α-hydroxyacids like glycolic, lactic, malic, citric, and tartaric acid; urea; co-enzyme QlO; or mixtures of these substances.
18. The use of the formulation according to claims 1-17, for reduction of body weight.
19. The use of the formulation according to claims 1-17, for reduction of cellulite.
PCT/HR2009/000005 2009-02-24 2009-02-24 Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite WO2010097643A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/HR2009/000005 WO2010097643A1 (en) 2009-02-24 2009-02-24 Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/HR2009/000005 WO2010097643A1 (en) 2009-02-24 2009-02-24 Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite

Publications (1)

Publication Number Publication Date
WO2010097643A1 true WO2010097643A1 (en) 2010-09-02

Family

ID=41212176

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HR2009/000005 WO2010097643A1 (en) 2009-02-24 2009-02-24 Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite

Country Status (1)

Country Link
WO (1) WO2010097643A1 (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012156913A1 (en) * 2011-05-18 2012-11-22 Slavko Ivkovic An antioxidant composition
WO2013055197A1 (en) * 2011-10-12 2013-04-18 Universidad Autonoma Del Estado De Hidalgo Base powder from the red raspberry rubus idaeus and activated micronized zeolite for attenuating nicotine addiction, method for the preparation thereof and use thereof
WO2013074046A1 (en) * 2011-08-08 2013-05-23 Mahmut Bilgic Pharmaceutical formulations comprising isoflavone
CN103642574A (en) * 2013-12-20 2014-03-19 江苏鹏飞海太机械有限公司 Loom lubricating oil
WO2015017336A1 (en) * 2013-07-29 2015-02-05 OmniGen Research, L.L.C. Combination and method for administration to an animal
US9375408B2 (en) * 2014-09-02 2016-06-28 Bhupinder Singh Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
WO2016183633A1 (en) * 2015-05-19 2016-11-24 Sndr Pty Ltd Skin cleansing composition
CN106268810A (en) * 2016-07-29 2017-01-04 华南理工大学 A kind of surface recombination modifies particle aggregate carrier material and preparation method and application
CN108997154A (en) * 2018-08-27 2018-12-14 山东祥维斯生物科技股份有限公司 Glycine betaine formulation preparation method with low sodium chloride content and agent of low hygroscopicity

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040699A1 (en) * 1996-04-25 1997-11-06 Unilever Plc Tea processing with zeolites
US20060153926A1 (en) * 2005-01-10 2006-07-13 Bascom Charles C Compositions, products and methods for controlling weight in a mammal
CN101218962A (en) * 2007-12-26 2008-07-16 中国科学院东北地理与农业生态研究所 A Feed Additive for Improving Milk Quality

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997040699A1 (en) * 1996-04-25 1997-11-06 Unilever Plc Tea processing with zeolites
US20060153926A1 (en) * 2005-01-10 2006-07-13 Bascom Charles C Compositions, products and methods for controlling weight in a mammal
CN101218962A (en) * 2007-12-26 2008-07-16 中国科学院东北地理与农业生态研究所 A Feed Additive for Improving Milk Quality

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200856, Derwent World Patents Index; AN 2008-J52094, XP002553961, LIZ; LIU C; SUN H: "Feedstuff additive for use in improving milk" *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012156913A1 (en) * 2011-05-18 2012-11-22 Slavko Ivkovic An antioxidant composition
WO2013074046A1 (en) * 2011-08-08 2013-05-23 Mahmut Bilgic Pharmaceutical formulations comprising isoflavone
US20150216921A1 (en) * 2011-10-12 2015-08-06 University of Hidalgo Base powder from the red raspberry rubus idaeus and activated micronized zeolite for attenuating nicotine addiction, method for the preparation thereof and use thereof
WO2013055197A1 (en) * 2011-10-12 2013-04-18 Universidad Autonoma Del Estado De Hidalgo Base powder from the red raspberry rubus idaeus and activated micronized zeolite for attenuating nicotine addiction, method for the preparation thereof and use thereof
EP2767281A4 (en) * 2011-10-12 2015-05-20 Univ Autonoma Del Estado De Hidalgo Base powder from the red raspberry rubus idaeus and activated micronized zeolite for attenuating nicotine addiction, method for the preparation thereof and use thereof
WO2015017336A1 (en) * 2013-07-29 2015-02-05 OmniGen Research, L.L.C. Combination and method for administration to an animal
CN103642574A (en) * 2013-12-20 2014-03-19 江苏鹏飞海太机械有限公司 Loom lubricating oil
US9375408B2 (en) * 2014-09-02 2016-06-28 Bhupinder Singh Methods of making a deuterated or a non-deuterated molecule and pharmaceutical formulations for treatment
US10781158B2 (en) 2014-09-02 2020-09-22 Bhupinder Singh Methods of protecting an organ using tetrahydrocurcumin and phosphatidylcholine
WO2016183633A1 (en) * 2015-05-19 2016-11-24 Sndr Pty Ltd Skin cleansing composition
CN106268810A (en) * 2016-07-29 2017-01-04 华南理工大学 A kind of surface recombination modifies particle aggregate carrier material and preparation method and application
CN108997154A (en) * 2018-08-27 2018-12-14 山东祥维斯生物科技股份有限公司 Glycine betaine formulation preparation method with low sodium chloride content and agent of low hygroscopicity
CN108997154B (en) * 2018-08-27 2021-05-11 山东祥维斯生物科技股份有限公司 Betaine formulations with low sodium chloride content and low hygroscopicity

Similar Documents

Publication Publication Date Title
WO2010097643A1 (en) Formulation based on micronized zeolite, green tea extract, and genistein as a therapeutic agent for reduction of body weight and cellulite
WO2010018418A1 (en) Formulation based on micronized clinoptilolite as therapeutic agent providing highly bioavailable silicon
IL260028B1 (en) Skin care preparations for babies
CN115607510B (en) High-concentration oleanolic acid nanoemulsion composition and preparation method thereof
US20190008907A1 (en) Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases
MX2008012654A (en) Novel compositions for hair disorders and process of preparation thereof.
CN102342993B (en) Anti-sensitization and restoration external preparation for skin
CA3148643A1 (en) Topical formulations comprising cannabidiol, method of preparing the composition and use thereof
WO2019234743A1 (en) Anti-inflammatory synergistic compositions comprising cannabinoids and licorice
CN101842089A (en) Methods for stimulating synthesis of pro-collagen or collagen and hyaluronic acid
US20040214750A1 (en) Medicaments for healing skin conditions in humans
WO2014095049A1 (en) Compositions for the treatment of dermatological conditions, disorders or diseases
EP2885004A1 (en) Companion cosmetic compositions
US20060083708A1 (en) Composition using mineral salts for cosmetic or therapeutic treatment
ES2340510T3 (en) USE OF RENTAL-FURANS FOR THE PREPARATION OF A MEDICINAL PRODUCT INTENDED FOR THE TREATMENT OF OBESITY AND FOR THE COSMETIC TREATMENT OF THE EXCEESS OF WEIGHT.
US8383166B2 (en) Stable hydrophobic topical herbal formulationn
JP2015513558A (en) Beauty composition
Semkina Ointments, gels, liniments, and creams containing phytopreparations (a review)
US8507007B2 (en) Dermatological composition that can be used in particular for the care and prevention of eschars
Mascolo et al. Healing powers of aloes
EP0717613B1 (en) Stable composition containing wheat sprout juice and process for producing it
Haji et al. Ghee based nanostructured lipid carriers (NLCs) with improved wound-healing effects: Ghee based nanostructured lipid carriers (NLCs)
JP6853406B1 (en) Topical composition for antifolliculitis
ITUB20159582A1 (en) Composition, for topical use, useful for the prevention of inflammatory and / or infectious mucosal disorders.
ES2581180B1 (en) USE OF ORAL ALOE FOR HAIR IMPROVEMENT

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09785745

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 01/12/2011)

122 Ep: pct application non-entry in european phase

Ref document number: 09785745

Country of ref document: EP

Kind code of ref document: A1